| Symbol | QGEN |
|---|---|
| Name | QIAGEN N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | HULSTERWEG 82, VENLO, 5912 PL, Netherlands |
| Telephone | +31 773556600 |
| Fax | — |
| — | |
| Website | https://www.qiagen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001015820 |
| Description | Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The companys sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firms revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%). Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - QIAGEN N.V. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0000912938-26-000674 <b>Size:</b> 7 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Read moreParse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
Read moreQIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
Read more